UK-based Antiverse, abiotech company developing AI-designed therapeutic antibodies forhard-to-target disease targets, has closed a $9.3 million Series A round led bySoulmates Ventures, with participat…
Fonte: Tech.eu | Data: Tue, 03 Mar 2026 13:00:00 +0000